REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye
NCT ID: NCT03460548
Last Updated: 2020-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
26 participants
INTERVENTIONAL
2018-03-30
2019-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye
NCT02908282
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
NCT04701086
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
NCT00932477
Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
NCT02980224
Assessment of Efficacy and Safety of the Use of Two Eye Gel Products Containing 5% Dexpanthenol in Patients With Moderate to Severe Dry Eye Syndrome
NCT06210373
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remogen
Remogen
instil 1 drop of the product in each eye, 4 times per day
Cationorm
Cationorm
instil 1 drop of the product in each eye, 4 times per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remogen
instil 1 drop of the product in each eye, 4 times per day
Cationorm
instil 1 drop of the product in each eye, 4 times per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a score of ocular surface staining with fluorescein (OSSF) ≥ 4 and ≤ 9 on the Oxford scale
* With at least one objective sign of tear deficiency
* With Ocular Surface Disease Index (OSDI) score of ≥ 18
Exclusion Criteria
* Any other ocular surgery or ocular trauma within 6 months prior to selection
* Systemic or local use of one of the following medications: glucocorticosteroids, cyclosporine A, antibiotics, NSAIDs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TRB Chemedica
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe Baudouin, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Quinze-Vingts Hospital, Paris, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quinze-Vingts Hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOGA-CT-1501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.